6/13/2012 10:07:06 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung. scuPA reverses a defect in clot clearance that characterizes pleural loculation. The program is led by Dr. Steven Idell of The University of Texas Health Science Center at Tyler. ABL will develop the production cell line and manufacturing process followed by scale-up and manufacture of toxicology and cGMP clinical materials. The materials produced at ABL will be used to support an IND, and will be used in clinical trial testing.
comments powered by